Abstract:Background Aortic aneurysms and dissections are highly lethal diseases for which an effective treatment strategy is critically needed to prevent disease progression. The nucleotide‐binding oligomerization domain–like receptor pyrin domain containing 3 (NLRP3)–caspase‐1 inflammasome cascade was recently shown to play an important role in aortic destruction and disease development. In this study, we tested the effects of MCC950, a potent, selective NLRP3 inhibitor, on preventing aortic destruction and aortic aneurysm and dissection formation. Methods and Results In a model of sporadic aortic aneurysm and dissection induced by challenging wild‐type mice with a high‐fat, high‐cholesterol diet and angiotensin II infusion, MCC950 treatment significantly inhibited challenge‐induced aortic dilatation, dissection, and rupture in different thoracic and abdominal aortic segments in both male and female mice. Aortic disease reduction by MCC950 was associated with the prevention of NLRP3–caspase‐1 upregulation, smooth muscle cell contractile protein degradation, aortic cell death, and extracellular matrix destruction. Further investigation revealed that preventing matrix metallopeptidase 9 (MMP‐9) expression and activation in macrophages is an important mechanism underlying MCC950's protective effect. We found that caspase‐1 directly activated MMP‐9 by cleaving its N‐terminal inhibitory domain. Moreover, the genetic knockdown of Nlrp3 or Casp‐1 in mice or treatment of mice with MCC950 diminished the challenge‐induced N‐terminal cleavage of MMP‐9, MMP‐9 activation, and aortic destruction. Conclusions Our findings suggest that the NLRP3–caspase‐1 inflammasome directly activates MMP‐9. Targeting the inflammasome with MCC950 is a promising approach for preventing aortic destruction and aortic aneurysm and dissection development. Clinical Perspective What Is New? The nucleotide‐binding oligomerization domain–like receptor pyrin domain containing 3–caspase‐1 inflammasome activates matrix metallopeptidase 9. Caspase‐1 directly activates matrix metallopeptidase 9 by cleaving its N‐terminal inhibitory domain. MCC950 prevents challenge‐induced nucleotide‐binding oligomerization domain–like receptor pyrin domain containing 3–caspase‐1 inflammasome activation, aortic destruction, and aortic aneurysm and dissection formation. What Are the Clinical Implications? Targeting the nucleotide‐binding oligomerization domain–like receptor pyrin domain containing 3–caspase‐1 inflammasome with MCC950 is a promising approach for preventing aortic destruction and aortic aneurysm and dissection development. Introduction Aortic aneurysms and dissections (AADs) are life‐threatening cardiovascular diseases for which there is no effective pharmacologic therapy. 1 , 2 , 3 Therefore, developing an effective treatment strategy that prevents disease progression is critical. An increasing amount of evidence has indicated that the nucleotide‐binding oligomerization domain–like receptor pyrin domain containing 3 (NLRP3)–caspase‐1 inflammasome cascade, an important regulator of the inflammatory response, 4 , 5 plays an important role in vascular inflammation and aortic aneurysm formation in mice that were challenged with angiotensin II (AngII). 6 , 7 , 8 The NLRP3–caspase‐1 inflammasome has been shown to activate macrophages and promote aortic inflammation and destruction. 6 , 7 Furthermore, the NLRP3–caspase‐1 inflammasome also degrades contractile proteins in vascular smooth muscle cells (SMCs), leading to aortic dysfunction. 8 MCC950 is a novel, potent selective small‐molecule NLRP3‐inflammasome inhibitor 9 that wa -Abstract Truncated-

Integrated Proteomics Characterization of NLRP3 Inflammasome Inhibitor MCC950 in Monocytic Cell Line Confirms Direct MCC950 Engagement with Endogenous NLRP3

MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition

Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome

Pharmacological Inhibition of the Nod-Like Receptor Family Pyrin Domain Containing 3 Inflammasome with MCC950

Target of MCC950 in Inhibition of NLRP3 Inflammasome Activation: a Literature Review

MCC950 as a promising candidate for blocking NLRP3 inflammasome activation: A review of preclinical research and future directions

Therapeutic Potential of MCC950, a Specific Inhibitor of NLRP3 Inflammasome in Systemic Lupus Erythematosus

Design, synthesis and biological evaluation of sulfonylurea derivatives as NLRP3 inflammasome inhibitors

A phenotypic high-content, high-throughput screen identifies inhibitors of NLRP3 inflammasome activation

MCC950 attenuates doxorubicin-induced myocardial injury in vivo and in vitro by inhibiting NLRP3-mediated pyroptosis

The selective NLRP3 inhibitor MCC950 hinders atherosclerosis development by attenuating inflammation and pyroptosis in macrophages

A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases

Targeting the NLRP3 Inflammasome With Inhibitor MCC950 Prevents Aortic Aneurysms and Dissections in Mice.

UK5099 Inhibits the NLRP3 Inflammasome Independently of its Long-Established Target Mitochondrial Pyruvate Carrier

The Selective NLRP3 Inflammasome Inhibitor MCC950 Alleviates Cholestatic Liver Injury and Fibrosis in Mice

Covalent Targeting As a Common Mechanism for Inhibiting NLRP3 Inflammasome Assembly

The NLRP3-inflammasome inhibitor MCC950 improves cardiac function in a HFpEF mouse model

Degrading the key component of the inflammasome: Development of an NLRP3 PROTAC

Target Cell Activation of a Structurally Novel NOD-Like Receptor Pyrin Domain-Containing Protein 3 Inhibitor NT-0796 Enhances Potency

Functional Characterization of an Arylsulfonamide-Based Small-Molecule Inhibitor of the NLRP3 Inflammasome

A selective NLRP3 inflammasome inhibitor attenuates behavioral deficits and neuroinflammation in a mouse model of Parkinson's disease